Compare CMPR & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPR | FTRE |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | CMPR | FTRE |
|---|---|---|
| Price | $70.95 | $17.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 8 |
| Target Price | ★ $80.50 | $12.64 |
| AVG Volume (30 Days) | 190.6K | ★ 1.6M |
| Earning Date | 01-28-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $3,461,387,000.00 | $2,759,900,000.00 |
| Revenue This Year | $8.23 | $3.17 |
| Revenue Next Year | $4.83 | $0.04 |
| P/E Ratio | $52.61 | ★ N/A |
| Revenue Growth | ★ 3.65 | 1.88 |
| 52 Week Low | $35.21 | $3.97 |
| 52 Week High | $76.65 | $20.26 |
| Indicator | CMPR | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 79.10 |
| Support Level | $73.60 | $15.55 |
| Resistance Level | $76.60 | $18.29 |
| Average True Range (ATR) | 2.50 | 1.01 |
| MACD | -0.38 | 0.21 |
| Stochastic Oscillator | 18.06 | 89.96 |
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.